PPIDT00256
Drug Information
| Name | Albiglutide |
|---|---|
| Sequence | HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL |
| DrugBank_ID | DB09043 |
| Type | biotech |
| Indication | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Subcutaneous |
30 MG
|
| Injection, powder, for solution | Subcutaneous |
50 MG
|
| Powder, for solution | Subcutaneous |
30 mg / 0.5 mL
|
| Powder, for solution | Subcutaneous |
50 mg / 0.5 mL
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
30 mg/0.5mL
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
50 mg/0.5mL
|